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‘‘Let it … be borne in mind how
infinitely complex and close-fitting
are the mutual relations of all
organic beings to each other and to
their physical conditions of life; and
consequently what infinitely varied
diversities of structure might be of
use to each being under changing
conditions of life.’’
— Charles Darwin,
On the Origin of Species
November 24, 2008, marked the 149th
anniversary of the first publication of
Charles Darwin’s seminal work entitled
‘‘On the Origin of Species.’’ The above
quote comes from Darwin’s answer to his
question about how the struggle for exis-
tence might shape patterns of variation. Of
course, in the 19th century, Darwin was
making inferences simply based on obser-
vations of morphological variation. Yet, if
he were alive today, he would be struck by
how prescient his statement was, even as
applied to questions about the long co-
evolution of primates and viral pathogens,
including lentiviruses [1].
The human genome was originally
thought to be structurally stable, but it
turns out to be quite dynamic, with many
genomic regions duplicated or deleted
among individuals to the extent that they
exist in variable copy numbers. Within
these copy number variations (CNVs),
genes that encode proteins involved in
immune responses are over-represented
[2], including chemokines that play key
roles in host defense against infectious
diseases [3–5]. This observation implies
that our genomes have DNA sequences
that may memorialize immune strategies
used to combat ancient pathogens. The
past 5 years have witnessed an intense
interest in understanding the extent of
CNV in primate genomes [6,7] and their
contributions to disease susceptibility in
humans [8]. In this issue of PLoS Genetics,
Degenhardt and colleagues provide a link
between CNV and disease susceptibility in
non-human primates [9].
Asian macaques—including rhesus, pig-
tail, and cynomolgus—are commonly used
as animal models to study the determi-
nants of AIDS pathogenesis and evaluate
HIV-1 vaccine candidates. After being
challenged with Simian Immunodeficien-
cy Virus (SIV)—the simian counterpart of
HIV—some macaques rapidly develop
features similar to AIDS, whereas others
do so more slowly. A similar clinical
conundrum exists in humans, as many
people who are HIV-1–positive progress
rapidly to AIDS, whereas others resist
disease progression, despite not receiving
antiretroviral therapy. Both viral and host
factors contribute to the variability in
AIDS progression rates in humans [10].
Among host factors that may contribute
to variable HIV-AIDS susceptibility, sig-
nificant attention has focused on the role
of variations in genes that influence HIV
transmission, such as the genes that
encode CC chemokine receptor 5
(CCR5), the major HIV co-receptor
required for cell entry of virus, and
CCR5 chemokine ligands such as CC
ligand 3 (CCL3) and its paralog CCL3L1
[10]. For example, homozygosity for a 32-
bp deletion in the coding sequence of
CCR5 abolishes CCR5 expression and
confers near-absolute protection against
acquiring HIV [10]. CCR5 ligands can
block entry of HIV into cells by ‘‘gum-
ming’’ up the site on CCR5 to which
HIV-1 binds and by reducing cell surface
expression of CCR5 [5]. Among the
chemokines that bind to CCR5, CCL3L1
has the most potent HIV-suppressive
properties [5]. Additionally, CCL3L genes
were shown to be subject to CNV in
humans and chimpanzee [11,12]. A low
copy number of the CCL3L1-containing
segmental duplication was found to be
associated with reduced CCL3/CCL3L1
chemokine levels, reduced chemotaxis of
CCR5-expressing cells, and reduced pro-
portions of HIV target cells that express
CCR5 [5,11,12]. This discovery prompted
investigators to inquire whether intersub-
ject differences in CCL3L1 copy number
might be a basis for variable HIV-AIDS
susceptibility. A low copy number of the
CCL3L1-containing segmental duplication
was shown to be associated with or
correlate with an increased risk of acquir-
ing HIV infection [12–17], a faster rate of
progression to AIDS or CD4+ T cell
depletion [12,16,18,19], higher HIV viral
loads [12,13,20], lower HIV-specific im-
mune responses [20], and lower cell-
mediated immune responses [18].
In this issue of PLoS Genetics, Degenhardt
and colleagues tested whether a low CCL3L
copy number was associated with a faster
rate of progression to AIDS in macaques
challenged experimentally with SIV [9].
They found that macaques with a low copy
number of CCL3L genes experience a
significantly more rapid rate of progression
to experimental AIDS, with the CCL3L
CNV accounting for ,18% of the variabil-
ity in experimental AIDS progression rates.
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quickly to experimental AIDS than do
Chinese macaques [21]. Degenhardt et al.
suggest that the lower CCL3L copy num-
ber in Indian rhesus macaques may
underlie the more rapid progression to
AIDS in Indian versus Chinese macaques.
Thus, in addition to serving as a determi-
nant of interindividual differences in the
Figure 1. Comparative genomics of primate CCL3L and CCL4L loci. (A) Comparison of CCL3L and CCL4L in human and nonhuman primates.
The top panel shows a schema of the chemokine locus at human chromosome 17q12 based on the NT_010799.14 contig. CCL3 and CCL4 exist as
single-copy genes per haploid genome. The genes encoding the non-allelic isoforms of CCL3 (National Center for Biotechnology Information gene ID
given in parentheses) are denoted as CCL3L1 (6349), CCL3L2 (390788), and CCL3L3 (414062) and those of CCL4 are denoted as CCL4L1 (9560) and
CCL4L2 (388372). The middle panel shows a schema of the CCL3L and CCL4L locus in chimpanzee based on the chromosome 17NW_001226927.1
contig. CCL3L orthologs (denoted as ‘‘1’’ and ‘‘2’’) map , 1.6 Mb apart in this contig. In contrast to the human locus, chimpanzee contigs lack CCL3L2.
The bottom panel shows a schema of the CCL3L and CCL4L locus in rhesus monkey based on chromosome 16 NW_001103987 contig. Of note, other
orthologs of CCL3L and CCL4L were found in two other rhesus contigs (NW_001103644.1 and NW_001102959). CpG islands found in primate CCL3L
and CCL4L loci are also depicted. Distances between genes are approximate, and the map is not to scale. The arrows denote the orientation of the
genes. k, kb; M, Mb. (B and C) Schematic representation of genomic and mRNA structure of human CCL3L and CCL4L genes that have mRNA splicing
patterns that are similar (B) or dissimilar (C) to CCL3 and CCL4. Exons are represented as boxes and introns as connecting lines labeled with Roman
numbers; the splicing pattern is denoted by the dashed lines. CCL3L1, CCL3L3, and CCL4L2 are each composed of three exons, and the start codon
(denoted with an arrow) is located in the first exon. CCL4L1 has a transition in the splicing acceptor site located in intron II (AGRGG, indicated in red),
which results in the generation of aberrantly spliced transcripts that use alternative acceptor sites located either in the intron II or in the third exon
[26]. CCL3L2 was previously considered as a pseudogene [5]. However, recent studies in our lab suggest that it has a four exon structure and is
predicted to transcribe alternatively spliced mRNA species with open reading frames (ORFs) that contain chemokine-like domains [16]; CCL3L2 mRNA
transcripts originate from two novel upstream exons (designated as 1A and 1B) and are linked to the second and third exons, which are homologous
to exons 2 and 3 found in CCL3L1 or CCL3L3. (D) Nucleotide sequence of human CCL3L1 (or CCL3L3) and its alignment with four distinct chimpanzee
CCL3L (chCCL3L) orthologous genes from the translation initiation site until the start of intron 1. The translational start codon in hCCL3L1 is
underlined. Horizontal arrows delimit the exon–intron boundaries. Dashes indicate deletions. Polymorphic sites relative to the hCCL3L1 are shown in
red. The vertical arrow represents the site for signal peptidase cleavage. chCCL3L ortholog 1 is predicted to encode a chemokine with amino acids that
are shared with both hCCL3L1 and hCCL3. chCCL3L ortholog 2 has a deletion of 17 nucleotides (relative to hCCL3L1) that may lead to loss of the signal
peptide cleavage motif. Notably, two additional and different CCL3L orthologs were found in two independent chimpanzee contigs, denoted as
NW_001227489.1 (ortholog 3) and NW_001227474.1 (ortholog 4), which have a mutation at the translation initiation site (shown in purple) and differ
from each other in the splicing donor site of intron 1 (shown in blue) and other genomic regions (unpublished data). Of note, all four chCCL3L1
orthologs had sequences that were completely homologous to the primer–probe sets used to detect CCL3L CNV in humans and chimpanzee
previously [12] and by Degenhardt et al. [9]. All the chimpanzee orthologs are also predicted to encode transcripts with potential ORFs with
chemokine-like domains. The accession numbers for the predicted ORFs encoded by chimpanzee CCL3L orthologs 1, 2, 3, and 4 are NP_001029254,
XP_001152451, XP_001172388, and XP_001172226, respectively.
doi:10.1371/journal.pgen.1000359.g001
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gene dose may account for some of the
observed interpopulation differences in
simian AIDS progression rates.
Previous studies have shown that there is
a clear genetic distinction between rhesus
macaques that originate from India versus
China [22]. Thus, population structure is a
possible confounding variable whenever
phenotypic differences between these popu-
lations are investigated. Degenhardt et al.
controlled for population structure using a
battery of microsatellites and demonstrated
that the CCL3L CNV was a better predictor
of outcome than population affiliation.
While other genes may also influence
p r o g r e s s i o nt os i m i a nA I D Si ne x p e r i m e n -
tally infected rhesus macaques [23], Degen-
h a r d te ta l . ’ sr e s u l t ss h o wt h a tt h eCCL3L
CNV has strong effects on progression to
simian AIDS. These results have practical
implications for efforts to develop an
effective HIV vaccine. To distinguish more
clearly between vaccine efficacy and intrin-
sic variation in host response, it may be
important to stratify rhesus macaques by
CCL3L CNV.
Understanding the role of chemokine
CNVs in primate disease is made more
complicated by several observations. At
least in humans, there are multiple CCL3L
(CCL3L1, CCL3L2,a n dCCL3L3)a n d
CCL4L (CCL4L1 and CCL4L2, paralogs of
CCL4) genes, which are found on chromo-
some 17q12; a similar diversity might exist
in nonhuman primates (Figure 1A). How-
ever, the human CCL3L-CCL4L–contain-
ing locus has been subjected to complex
homologous recombination events [24,25],
such that individuals may vary not only in
the total copy number of CCL3L and
CCL4L genes but also their individual
components [11,16]. Furthermore, the
mRNA structure of the different CCL3L
and CCL4L genes appears to vary
(Figure 1B and 1C). For example, while
human CCL4L1 and CCL4L2 share 100%
sequence identity in the coding regions, a
fixed mutation at the intron–exon bound-
ary of CCL4L1 results in the production of
aberrantly spliced transcripts (Figure 1B
and 1C), and a higher CCL4L1 copy
number has been associated with an
increased risk of acquiring HIV infection
[26] and faster rate of progression to AIDS
[16]. With these features in mind, future
studies will need to consider such questions
as: Are the different copies of CCL3L and
CCL4L in rhesus macaques identical or do
they encode transcripts/proteins with dif-
ferent functions? How many of these copies
areactuallypseudogenes?Similartowhat is
observed in humans [16,26], could CCL4L
genes also contribute to simian AIDS
independently of or in combination with
distinct CCL3L genes? Could such com-
plexity also confound genotype–phenotype
studies in humans that investigate the
relationship between CCL3L or CCL4L
CNV with disease susceptibility? In addi-
tion to these CCL3L-CCL4L–related genetic
factors that may complicate the analyses of
association studies, there might be other
confounders to consider. For example, co-
infectionwith otherviruses (e.g., hepatitis C
virus [HCV]) may modify the association
between CCL3L1 copy number and risk of
acquiring HIV infection [17].
Using real-time PCR-based approaches,
Degenhardt et al. confirmed an earlier
report that chimpanzees have variable
copy numbers of CCL3L genes [9,12], as
do other nonhuman primates including
orangutan, African green monkey, and
Sooty Mangabey; on average the CCL3L
copy numbers in nonhuman primates are
much higher than those found in human
populations [9,12]. Furthermore, analyses
of the chimpanzee genome (from the Clint
reference sequence) revealed at least four
distinct CCL3L genes (Figure 1D). These
results differ with those of Perry et al.,
who, using an array-based method, found
that chimpanzees have two CCL3L copies
per diploid genome [7]. These contrasting
results underscore the challenges of accu-
rately quantifying CNVs, a particularly
important issue given the intense interest
in understanding the role of CNVs in
disease susceptibility [8].
One possible reason for the extensive
variability in CCL3L copy number in
primates may reflect that the variability
represents an ancient host defense mech-
anism. While this hypothesis needs to be
tested with additional empirical data, it is
consistent with the observation that there
is a parallel to primate chemokine CNV in
viruses: many viral pathogens have hi-
jacked DNA sequences found in primates
and adapted them to encode chemokine
receptors and chemokines that specifically
target and, in some cases, neutralize the
primate chemokine system [27]. These
viral-encoded antichemokine strategies
highlight the importance of the chemokine
system in host defense against infections.
Darwin, an astute observer of nature,
might ask, ‘‘Why does there appear to be
so much structural variation for genes
encoding chemokines?’’ The ancient and
dynamic battle between mammalian hosts
and pathogens has exerted unrelenting
selection pressure on the host genome,
promoting the development of a complex
and adaptable immune system. Converse-
ly, the successful replication and persis-
tence of latent viruses within the mamma-
lian host implies that they have evolved
the means to evade or manipulate host
immune defenses. In the case of viruses, it
is clear that they have targeted the
immune responses mediated by chemo-
kines [27]. Is the expansion and diversifi-
cation of the chemokine gene family, as a
consequence of gene duplication [3,4],
evidence of the co-evolution of host
defenses and viral pathogens? The elegant
study by Degenhardt et al. gets us closer to
answering this question, but much work
remains. Nevertheless, Darwin would be
pleased that the paradigm he established
more than a century ago continues to be
robust for explaining the ‘‘varied diversi-
ties of structure.’’
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